Table 4 Annual per capita costs of chemotherapy and immunotherapy for metastatic melanoma
Patients | Stays | Annual per capita cost | |||
|---|---|---|---|---|---|
National tariff | ENCC | Adjusted ENCC | |||
Ipilimumab | |||||
Pre-progression | 55 | 165 | € 64,017 | € 3949 | € 63,895 |
Acquisition | (0.8%) | (0.6%) | € 62,215 | NA | € 62,215 |
Administration | € 1802 | NA | € 1680 | ||
Post-progression | 348 | 949 | € 43,735 | € 2529 | € 43,657 |
Acquisition | (6.9%) | (2.6%) | € 42,530 | NA | € 42,530 |
Administration | € 1205 | NA | € 1127 | ||
Fotemustine | |||||
Pre-progression | 139 | 541 | € 5194 | € 5937 | € 5044 |
Acquisition | (1.9%) | (2.0%) | € 2372 | NA | € 2372 |
Administration | € 2822 | NA | € 2672 | ||
Post-progression | 969 | 3192 | € 3432 | € 3603 | € 3337 |
Acquisition | (19.1%) | (8.7%) | € 1696 | NA | € 1696 |
Administration | € 1736 | NA | € 1641 | ||
Other chemotherapies a | |||||
Pre-progression | 1475(20.1%) | 4845(18.0%) | € 3378 | € 6205 | € 3252 |
Post-progression | 2052(40.5%) | 10,214(28.0%) | € 2736 | € 5292 | € 2601 |